Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $57.50.

Several equities analysts recently commented on COLL shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday.

Institutional Trading of Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in COLL. Group One Trading LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at about $28,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 418 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Collegium Pharmaceutical by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the last quarter.

Collegium Pharmaceutical Stock Down 2.3%

COLL stock traded down $0.85 on Thursday, hitting $35.44. 12,499 shares of the company’s stock were exchanged, compared to its average volume of 470,191. Collegium Pharmaceutical has a 12-month low of $29.19 and a 12-month high of $50.79. The firm has a 50 day moving average price of $34.78 and a two-hundred day moving average price of $37.64. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The stock has a market cap of $1.15 billion, a P/E ratio of 17.36 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period in the prior year, the company posted $1.49 EPS. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, equities research analysts expect that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.